TY - JOUR
T1 - Invasive Lobular Breast Carcinoma
T2 - Pleomorphic Versus Classical Subtype, Associations and Prognosis
AU - Liu, Ying L.
AU - Choi, Christine
AU - Lee, Shing M.
AU - Zhong, Xiaobo
AU - Hibshoosh, Hanina
AU - Kalinsky, Kevin
AU - Connolly, Eileen P.
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2018/4
Y1 - 2018/4
N2 - Although pleomorphic compared with classic histology is considered a poor prognostic factor in lobular breast cancer, studies are small and conflicting. In our retrospective review, we found that progression-free survival was worse in the pleomorphic group; however, these differences disappeared after adjustment for cancer stage, suggesting that pleomorphic histology does not independently predict clinical outcomes. Background: Invasive pleomorphic lobular carcinoma (IPLC) has been associated with a worse prognosis compared with classic invasive lobular carcinoma (cILC); however, studies are small and conflicting. We seek to examine the prognosis of women with IPLC compared with cILC. Methods: A retrospective review of women with breast cancer at a single institution from 2003 to 2012 identified 193 women with invasive lobular carcinoma (ILC). IPLC was defined as ILC with a pathological description of primarily pleomorphic features and Nottingham histological grade score of 7, 8, or 9 or overall grade of 3 or mixed classic/pleomorphic features and overall grade of 3. All others were designated cILCs. Clinicopathologic variables, progression-free survival (PFS), per STEEP criteria, and overall survival (OS), using all-cause mortality, were examined in both groups. Results: Of the 193 women, 46 (24%) had IPLC and 147 (76%) had cILC. The IPLC group had significantly higher stage at diagnosis and more Hispanic women, but there were no differences in other clinicopathologic features or treatment. Median follow-up was 57 months (0.1-155 months). In univariate analysis, IPLC was associated with worse PFS (log-rank P =.09, Wilcoxon P =.01) but no significant differences in OS (log-rank P =.20, Wilcoxon P =.16). In multivariate models adjusting for stage, IPLC was not significantly associated with PFS (hazard ratio [HR] 1.43; 95% confidence interval [CI], 0.73-2.79; P =.30) or OS (HR 1.52; 95% CI, 0.58-4.01; P =.40). Conclusions: IPLC was initially associated with worse PFS, but this was attenuated after adjustment for cancer stage, and there were no differences in OS.
AB - Although pleomorphic compared with classic histology is considered a poor prognostic factor in lobular breast cancer, studies are small and conflicting. In our retrospective review, we found that progression-free survival was worse in the pleomorphic group; however, these differences disappeared after adjustment for cancer stage, suggesting that pleomorphic histology does not independently predict clinical outcomes. Background: Invasive pleomorphic lobular carcinoma (IPLC) has been associated with a worse prognosis compared with classic invasive lobular carcinoma (cILC); however, studies are small and conflicting. We seek to examine the prognosis of women with IPLC compared with cILC. Methods: A retrospective review of women with breast cancer at a single institution from 2003 to 2012 identified 193 women with invasive lobular carcinoma (ILC). IPLC was defined as ILC with a pathological description of primarily pleomorphic features and Nottingham histological grade score of 7, 8, or 9 or overall grade of 3 or mixed classic/pleomorphic features and overall grade of 3. All others were designated cILCs. Clinicopathologic variables, progression-free survival (PFS), per STEEP criteria, and overall survival (OS), using all-cause mortality, were examined in both groups. Results: Of the 193 women, 46 (24%) had IPLC and 147 (76%) had cILC. The IPLC group had significantly higher stage at diagnosis and more Hispanic women, but there were no differences in other clinicopathologic features or treatment. Median follow-up was 57 months (0.1-155 months). In univariate analysis, IPLC was associated with worse PFS (log-rank P =.09, Wilcoxon P =.01) but no significant differences in OS (log-rank P =.20, Wilcoxon P =.16). In multivariate models adjusting for stage, IPLC was not significantly associated with PFS (hazard ratio [HR] 1.43; 95% confidence interval [CI], 0.73-2.79; P =.30) or OS (HR 1.52; 95% CI, 0.58-4.01; P =.40). Conclusions: IPLC was initially associated with worse PFS, but this was attenuated after adjustment for cancer stage, and there were no differences in OS.
KW - Histology
KW - Risk factor
KW - Staging
KW - Survival
KW - Tumor grade
UR - https://www.scopus.com/pages/publications/85023629094
U2 - 10.1016/j.clbc.2017.06.006
DO - 10.1016/j.clbc.2017.06.006
M3 - Article
C2 - 28720418
AN - SCOPUS:85023629094
SN - 1526-8209
VL - 18
SP - 114
EP - 120
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
IS - 2
ER -